Spotlight Growth
No Result
View All Result
Monday, March 27, 2023
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
No Result
View All Result
No Result
View All Result
Home Bio/Med/Pharma

Decibel Therapeutics (NASDAQ: DBTX) Shares Positive Interim Data of its Ongoing Phase 1b Trial of DB-020

by admin
June 28, 2022
in Bio/Med/Pharma
0
Decibel Therapeutics NASDAQ DBTX Interim Data Phase 1b DB 020 Spotlight Growth

Decibel Therapeutics NASDAQ DBTX Interim Data Phase 1b DB 020 Spotlight Growth

Decibel Therapeutics, Inc. (NASDAQ: DBTX) is engaged as a clinical-stage biotechnology company, which is focused on the research and development of innovative treatments for restoring and improving hearing and balance issues. Shares of the auditory treatment company are rallying 24% through afternoon trading on Tuesday, June 28, 2022. Over the past three months, Decibel Therapeutics has seen average daily volume of 71,840 shares. However, volume of 397,469 shares or dollar volume of around $1.07 million, has already exchanged hands through afternoon trading.

Shares of Decibel Therapeutics are gaining after the company released positive top-line results from an interim analysis of its ongoing Phase 1b clinical trial of DB-020, a novel treatment designed to help protect against hearing loss in patients undergoing cisplatin Chemotherapy. Although cisplatin is among the most commonly used chemotherapeutic agents, it can have severe side effects including ototoxicity, which can lead to permanent hearing loss.

The interim analysis shows that 87% of patients suffering from ototoxicity in their placebo-treated ear were protected from the disease in their DB-020-treated ear. The data supports continuing to develop DB-020 as a potential treatment against hearing loss in patients undergoing cisplatin chemotherapy. Furthermore, DB-020 was shown to be well-tolerated with only mild to moderate adverse effects in some patients.

“These data support the approach and rationale for DB-020 and represent an important step forward in the development of DB-020 for patients receiving cisplatin chemotherapy. We are tremendously encouraged by the favorable safety profile and protection against ototoxicity we have observed in the trial as of the interim analysis,” said John Lee, Chief Development Officer of Decibel. “These promising data support continued development of DB-020 to prevent or minimize cisplatin-induced hearing loss, an irreversible condition for which there are currently no available treatments.”

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

Tags: biopharmaceuticalsbiotechcisplatincommon stockday tradingDBTXDBTX stockDecibel Therapeuticsemerging growthhearing lossinvestinginvesting newsinvestmentmedicalmicrocap stocksNASDAQnewsototoxicitypharmaceuticalspublic companyservicessmall cap companiessmall cap stockssmall capsSpotlight GrowthSpotlight Growth Stocksstock marketstock market newsstocksstocks to watchtechTechnologytradingtreatmentwebull wallstreetbets
  • Trending
  • Comments
  • Latest
Asure Software NASDAQ ASUR Human Capital Management HCM Industry Spotlight Growth

Asure Software (NASDAQ: ASUR) is Expanding to Meet the Rising Demand for Human Capital Management Software

September 27, 2022
OLB Group NASDAQ OLB Cuentas NASDAQ CUEN Partnership Fintech Spotlight Growth

OLB Group (NASDAQ: OLB) and Cuentas (NASDAQ: CUEN) Team Up to Bring Fintech Solutions to Over 32,000 Bodegas Across the United States

October 6, 2022
Siyata Mobile NASDAQ SYTA SYTAW SD7 VK7 Purchase Orders Spotlight Growth

New Purchase Orders for SD7 Rugged Device, VK7, and Other Accessories Boost Siyata Mobile’s Outlook (NASDAQ: SYTA)

December 14, 2021
Telcoin TEL Crypto Spotlight Growth

Telcoin (TEL) Quietly Leads a Crypto Remittance Revolution

June 15, 2021
Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

0
Safe-T SFET NASDAQ UN Presentation

Safe-T (NASDAQ: SFET) Has Been Selected to Present at the United Nations’ Office of Information and Communications Technology Event

0
Safe-T Group SFET Q4 FY 2020 Financial Results

Safe-T Group (NASDAQ: SFET) Reports Fourth Quarter and Full Year 2020 Financial Results

0
Safe-T Group NASDAQ SFET FY 2020 Prelim

Safe-T Group Ltd. (NASDAQ: SFET) Estimates Record-High Annual Revenues of Approximately $4.9 Million Representing ~50% Growth YoY 2020

0
Is U.S. Government Trying to Ban Crypto Spotlight Growth

Is The U.S. Government Trying to Ban Crypto?

March 23, 2023
Bioadaptives OTC Pink BDPT LOI World Wellness Health and Wellness Spotlight Growth

Bioadaptives (OTC Pink: BDPT) Signs LOI with World Wellness, LLC to Develop New Health and Wellness Products

March 23, 2023
JanOne NASDAQ JAN Sells ARCA Recycling Business Focus on Biopharma Spotlight Growth

JanOne (NASDAQ: JAN) Sells ARCA Recycling Business to VM7, Will Focus on Budding Biopharmaceuticals Business

March 22, 2023
89bio NASDAQ ETNB Phase 2b ENLIVEN Trial Pegozafermin NASH Spotlight Growth

89bio (NASDAQ: ETNB) Reports Phase 2b ENLIVEN Trial of Pegozafermin Achieved Primary Endpoints For Treatment of Nonalcoholic Steatohepatitis (NASH)

March 22, 2023

Recent News

Is U.S. Government Trying to Ban Crypto Spotlight Growth

Is The U.S. Government Trying to Ban Crypto?

March 23, 2023
Bioadaptives OTC Pink BDPT LOI World Wellness Health and Wellness Spotlight Growth

Bioadaptives (OTC Pink: BDPT) Signs LOI with World Wellness, LLC to Develop New Health and Wellness Products

March 23, 2023

Categories

  • Bio/Med/Pharma
  • Cannabis
  • Commodities
  • Consumer Goods
  • Crowdfunding
  • Crypto Cheat Sheets
  • Cryptocurrency
  • Earnings
  • Education
  • Entertainment
  • Financials
  • Market News
  • Opinion
  • Politics
  • Real Estate
  • Split Watch
  • Sponsored
  • Store
  • Technology
  • Uncategorized
  • Venture Capital/Private Equity (VC/PE)

Site Navigation

  • Disclosures
  • Terms Of Service
  • Privacy Policy
  • Contact Us

Copyright © 2017-2022 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

No Result
View All Result
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener

Copyright © 2017-2022 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

Newsletter Signup

Subscribe to our weekly newsletter below and never miss the latest small/micro-cap analysis and investment news from Spotlight Growth.

Enter your email address

Thanks, I’m not interested